Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HIV Infection The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements 2. Male or non-pregnant, non-lactating females. 3. Aged between 18 to 65 years, inclusive. 4. Documented HIV-1 infection 5. Plasma HIV RNA less than 40 copies/mL (note retesting of screening viral load is allowed). 6. CD4 count > 100 at screening (note retesting of screening CD4 count is allowed). 7. Receiving an antiretroviral regimen of Truvada and atazanavir/ritonavir for more than 3 months. 8. Serum total bilirubin concentration greater than 25 micromol/L 9. Agrees not to change regimen, outside the study recommendations, from baseline until end of the treatment period unless this is medically indicated as decided by their treating physician  Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic disorders or malignancy. 2. Body mass index (BMI) >35 kg/m2 3. Presence of any current active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions: • Stable cutaneous Kaposi's Sarcoma 4. Clinically relevant alcohol or drug use (positive urine drug screen, with the exception of cannabinoids) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. 5. The use of zinc supplements for 1 month before screening and disallowed concomitant therapy (See Concomitant Medication and treatment, section 5.2) or medication that may interfere with the study results (as determined by the principal investigator). 6. Females of childbearing potential who are not using effective non-hormonal birth control methods or not willing to continue using these birth control methods for at least 14 days after the end of the treatment period. 7. Previous allergy to any of the constituents of the zinc sulphate tablets administered in this trial. 8. Subjects with laboratory evidence of significantly decreased hepatic or renal function (as determined by the principal investigator). 9. Exposure to any investigational drug or placebo within 4 weeks of first dose of study drug